Novocure NVCR 深 沪
已收盘 08-01 16:00:00 美东时间
11.32
-0.250
-2.16%
华盛通- 最 高11.55
- 今 开11.35
- 成交量 206.15万股
- 最 低 11.065
- 昨 收 11.57
- 总市值 12.57亿
- 52周最高 34.13
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 10.91
- 委 比 -23.46%
- 总股本 1.11亿
- 历史最高 232.76
- 量 比 0.64
- 振 幅 4.19%
- 历史最低 5.95
- 每 手 1
- 风险率 4.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top 3 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to b...
07-28 18:52
美股周涨跌榜 | 本周飙升568%！Abivax S.A.新药III期研究成功；CRO股Medpace周涨超43%
本周飙升568%！生物技术公司Abivax S.A.溃疡性结肠炎口服药物III期研究成功；CRO股Medpace周涨超43%，Q2营收和EBITDA均超预期>>
07-26 10:23
Wells Fargo Downgrades NovoCure to Equal-Weight, Lowers Price Target to $14.5
Wells Fargo analyst Larry Biegelsen downgrades NovoCure (NASDAQ:NVCR) from Overweight to Equal-Weight and lowers the price target from $40 to $14.5.
07-25 21:22
NocoCure shares are trading lower. The company reported Q2 financial results.
NocoCure shares are trading lower. The company reported Q2 financial results.
07-24 23:05
Earnings Scheduled For July 24, 2025
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is likely to repo...
07-24 16:32
NovoCure Earnings Preview
NovoCure (NASDAQ:NVCR) is set to give its latest quarterly earnings report on T...
07-24 05:02
Ladenburg Thalmann Initiates Coverage On NovoCure with Buy Rating, Announces Price Target of $30
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on NovoCure (NASDAQ:NVCR) with a Buy rating and announces Price Target of $30.
07-08 20:17
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
Demystifying NovoCure: Insights From 4 Analyst Reviews
Ratings for NovoCure (NASDAQ:NVCR) were provided by 4 analysts in the past thre...
06-28 02:01
Piper Sandler Reiterates Overweight on NovoCure, Maintains $34 Price Target
Piper Sandler analyst Jason Bednar reiterates NovoCure (NASDAQ:NVCR) with a Overweight and maintains $34 price target.
06-28 00:35
